According to the CIHR press release, Harper's investment appears to be geared towards developing personalized medicine not only for cancer, but also for a wide range of diseases including cardiovascular diseases, neurodegenerative diseases, psychiatric disorder, diabetes, obestiy, arthritis, pain and Alzheimer's disease.